香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接於美國境內或有關刊發或派發屬違法的任何其他司法權區刊 發或派發。本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券之邀請或要約。 本公告並不構成或組成於美國境內或有關發售屬違法的任何其他司法權區出售證券的任何要約或 招攬購買或認購證券的一部分。本公告所述本公司股份並無亦不會根據1933年美國證券法（經修訂） （「美國證券法」）登記，且不得於美國境內提呈發售或出售，惟根據美國證券法登記規定進行登記者 或獲豁免遵守該等登記規定者除外。本公司無意根據美國證券法登記本公告內所指之任何證券，或 在美國境內進行證券公開發售。 CANbridge Pharmaceuticals Inc. 北海康成製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1228） 根據一般授權認購新股份 根據一般授權認購新股份 於2025年8月12日（交易時段前），本公司與認購人訂立認購協 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致之任何損失承擔任何責任。 自願性公告 獨家商業服務協議 本公告乃北海康成製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願作出，旨在向本公 司股東及潛在投資者提供有關本集團業務發展的最新資料。 於2025年8月11日，本集團的兩家附屬公司（「相關附屬公司」）與青島百洋醫藥股份有限公司（於深圳 證券交易所上市的公司，股票代碼：301015）（「百洋醫藥」）的一家附屬公司（「百洋附屬公司」）正式建 立戰略合作關係。上述各方已訂立一份戰略合作及獨家商業服務協議（「商業服務協議」），據此，相 關附屬公司已同意委任百洋附屬公司為獨家合同銷售組織(CSO)，於中國內地、香港及澳門（「相關地 區」）推廣本集團的若干產品，惟須受本集團相關成員公司與該等產品各自的授權方所訂立的上游授 權協議（包括（在適用情況下）相關授權方的同意）所規限。商業服務協議亦訂明，百洋附屬公司的聯屬 公司可按百洋的選擇擔任該等產品於相關地區的分銷商。 由於商業 ...

北海康成-B(01228)发布公告，于2025年8月12日上午9时正起短暂停牌。 ...

智通财经APP讯，北海康成-B(01228)发布公告，于2025年8月12日上午9时正起短暂停牌。 ...

格隆汇8月12日丨北海康成-B(01228.HK)发布公告，公司股份将于2025年8月12日（星期二）上午九时正 起在香港联交所暂停买卖，以待刊发一份载有公司内幕消息的公告。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致之任何損失承擔任何責任。 董事長 薛群博士 短暫停牌 應北海康成製藥有限公司（「本公司」）的要求，本公司股份將於2025年8月12日（星期二）上午九時正起 在香港聯合交易所有限公司暫停買賣，以待刊發一份載有本公司內幕消息的公告。 承董事會 北海康成製藥有限公司 CANbridge Pharmaceuticals Inc. 北海康成製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1228） 香港，2025年8月12日 於本公告日期，董事會包括執行董事薛群博士；非執行董事趙瑋女士；以及獨立非執行董事Richard James Gregory博士、James Arthur Geraghty先生、陳炳鈞先生及胡瀾博士。 ...

Group 1 - The company Beihai Kangcheng-B (01228.HK) announced that its shares will be suspended from trading starting at 9:00 AM on August 12, 2025 [1]

Summary of Key Points Core Viewpoint - As of August 11, a total of 142 stocks reached their 52-week highs, indicating a strong performance in the market, with notable leaders including Songjing Technology, Blue River Holdings, and Beihai Kangcheng-B, achieving high rates of increase in their stock prices [1]. Stock Performance Highlights - **Top Performers**: - Songjing Technology (01079) reached a closing price of 0.425, with a peak of 0.550, marking an increase of 123.58% - Blue River Holdings (00498) closed at 0.221, peaking at 0.249, reflecting an increase of 84.44% - Beihai Kangcheng-B (01228) closed at 1.670, with a peak of 2.120, showing an increase of 44.22% [1]. - **Additional Notable Stocks**: - Raffles Interior (01376) increased by 40.56% - Runhua International Holdings (00202) increased by 40.00% - Tianye Water Saving (00840) increased by 36.55% [1]. 52-Week High Rankings - The table lists various stocks that achieved their 52-week highs, with their respective closing prices, peak prices, and growth percentages, showcasing a diverse range of industries and companies [1][2][3][4]. 52-Week Low Rankings - In contrast, the report also highlights stocks that reached their 52-week lows, with companies like Jia Ding International Group (08153) and Hengtaiyu Group (08081) showing significant declines of -18.06% and -11.11% respectively [4].

Market Overview - The Hang Seng Index rose by 0.19%, gaining 47 points to close at 24,906 points, while the Hang Seng Tech Index increased by 0.11% [1] - Early trading volume in Hong Kong stocks reached HKD 121.3 billion [1] Lithium Sector - Ningde Times confirmed the suspension of its lithium mine in Jiangxi, leading to significant gains in lithium stocks, with Tianqi Lithium rising by 15% and Ganfeng Lithium increasing by 19% [1] Automotive Sector - XPeng Motors saw a 6.43% increase, with its new P7 model achieving over 10,000 pre-orders in under 7 minutes, indicating strong institutional confidence in the company's sales growth [1] Food and Beverage Sector - Ajisen China reported a 9.4% increase in stock price, expecting to turn a profit of up to RMB 40 million in the first half of the year [1] Paper Industry - Lee & Man Paper saw a stock price increase of over 5%, with a 0.7% year-on-year growth in net profit for the first half of the year, as institutions anticipate a new round of supply clearance driven by new national standards [1] Pharmaceutical Sector - North Sea Kangcheng-B experienced a surge of over 32%, with the first prescription for its product successfully launched, and the company is actively communicating with medical insurance payment departments [1] Alcohol Sector - Zhenjiu Lidou's stock rose by over 2%, although product sales pressure affected its first-half performance, with expectations for improvement in the second half due to new product contributions [1] Aluminum Sector - Rusal's stock increased by 8.45%, amid market attention on the upcoming meeting between the US and Russian presidents regarding sanctions on Rusal [1] Semiconductor Sector - The US Department of Commerce began issuing export licenses for NVIDIA's H20 chips to mainland China, leading to declines in semiconductor stocks, with Hua Hong Semiconductor dropping over 4% and SMIC falling by 3% at one point, ultimately closing down 0.16% [1] Real Estate Sector - Shimao Group's stock fell by over 15%, with July contract sales decreasing by approximately 27% year-on-year [2]

Core Viewpoint - Beihai Kangcheng-B (01228) has seen a significant increase in stock price, rising over 35% recently and accumulating a total increase of over 1300% year-to-date, indicating strong market interest and potential investor confidence in the company's future prospects [1] Company Summary - As of the latest report, Beihai Kangcheng's stock is trading at 1.71 HKD with a trading volume of 30.39 million HKD [1] - The National Medical Products Administration approved the company's application for injectable Velaglucerase beta (brand name: Gorenin) on May 15, which is intended for long-term enzyme replacement therapy for patients aged 12 and above with Type I and III Gaucher disease [1] - The first prescription for Gorenin was issued on July 3, with the first patient receiving treatment at Xinhua Hospital [1] Industry Context - The founder and CEO of Beihai Kangcheng highlighted the challenges in financing treatments for rare diseases, noting that relying solely on basic national health insurance is insufficient for addressing patient payment difficulties [1] - The company is actively engaging with health insurance payment departments to establish a more feasible payment mechanism for rare diseases, aiming to pave the way for a better commercial environment for rare diseases in China [1]